ATE402189T1 - Verbindungen und methoden zur wt1-spezifischen immuntherapie - Google Patents

Verbindungen und methoden zur wt1-spezifischen immuntherapie

Info

Publication number
ATE402189T1
ATE402189T1 AT01977493T AT01977493T ATE402189T1 AT E402189 T1 ATE402189 T1 AT E402189T1 AT 01977493 T AT01977493 T AT 01977493T AT 01977493 T AT01977493 T AT 01977493T AT E402189 T1 ATE402189 T1 AT E402189T1
Authority
AT
Austria
Prior art keywords
methods
polypeptide
compounds
specific immunotherapy
compositions
Prior art date
Application number
AT01977493T
Other languages
English (en)
Inventor
Alexander Gaiger
Patricia Mcneill
Molly Smithgall
Gus Moulton
Thomas Vedvick
Paul Sleath
Sally Mossman
Lawrence Evans
A Spies
Jeremy Boydston
Original Assignee
Corixa Corp
Alexander Gaiger
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/684,361 external-priority patent/US7115272B1/en
Priority claimed from US09/685,830 external-priority patent/US7329410B1/en
Priority claimed from US09/785,019 external-priority patent/US7144581B2/en
Application filed by Corixa Corp, Alexander Gaiger filed Critical Corixa Corp
Application granted granted Critical
Publication of ATE402189T1 publication Critical patent/ATE402189T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4242—Transcription factors, e.g. SOX or c-MYC
    • A61K40/4243—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT01977493T 2000-10-06 2001-10-03 Verbindungen und methoden zur wt1-spezifischen immuntherapie ATE402189T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US09/684,361 US7115272B1 (en) 1998-09-30 2000-10-06 Compositions and methods for WT1 specific immunotherapy
US09/685,830 US7329410B1 (en) 1998-09-30 2000-10-09 Compositions and method for WT1 specific immunotherapy
US09/785,019 US7144581B2 (en) 2000-10-09 2001-02-15 Compositions and methods for WT1 specific immunotherapy
US09/938,864 US20030072767A1 (en) 1998-09-30 2001-08-24 Compositions and methods for WT1 specific immunotherapy

Publications (1)

Publication Number Publication Date
ATE402189T1 true ATE402189T1 (de) 2008-08-15

Family

ID=27505400

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01977493T ATE402189T1 (de) 2000-10-06 2001-10-03 Verbindungen und methoden zur wt1-spezifischen immuntherapie

Country Status (13)

Country Link
US (1) US20030072767A1 (de)
EP (1) EP1328287B1 (de)
JP (2) JP4130359B2 (de)
KR (1) KR100858231B1 (de)
CN (1) CN100545174C (de)
AT (1) ATE402189T1 (de)
AU (2) AU9660801A (de)
CA (1) CA2425072C (de)
DE (1) DE60135005D1 (de)
ES (1) ES2311027T3 (de)
MX (1) MXPA03002983A (de)
NZ (1) NZ540397A (de)
WO (1) WO2002028414A1 (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4932199A (en) 1998-07-31 2000-02-21 Haruo Sugiyama Cancer antigens based on tumor suppressor gene wt1 product
US7901693B2 (en) * 1998-09-30 2011-03-08 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7329410B1 (en) 1998-09-30 2008-02-12 Corixa Corporation Compositions and method for WT1 specific immunotherapy
US7655249B2 (en) * 1998-09-30 2010-02-02 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
EP1371664B1 (de) * 2001-03-22 2008-01-09 International Institute of Cancer Immunology, Inc. Wti-modifiziertes peptid
US7553494B2 (en) * 2001-08-24 2009-06-30 Corixa Corporation WT1 fusion proteins
WO2005001117A1 (ja) * 2003-06-27 2005-01-06 Haruo Sugiyama Ｗｔ１ワクチン適応患者の選択方法
US20050260217A1 (en) * 2004-03-04 2005-11-24 Corixa Corporation Co-encapsulated WT1 polypeptide and immunostimulant microsphere formulations and methods thereof
EP1801211A4 (de) * 2004-09-17 2008-06-11 Nec Corp Hla bindendes peptid, dieses codierendes dna-fragment und rekombinanter vektor
EP1951281B1 (de) * 2005-10-17 2015-04-15 Sloan Kettering Institute For Cancer Research Wt1 hla klasse ii-bindungspeptide und diese umfassende zusammensetzungen und verfahren
WO2007070907A2 (en) * 2005-12-21 2007-06-28 St. Anna Kinderkrebsforschung Therapeutic compositions
AU2007218649B2 (en) 2006-02-22 2013-01-10 International Institute Of Cancer Immunology, Inc. HLA-A*3303-restricted WT1 peptide and pharmaceutical composition comprising the same
EP2009100B1 (de) * 2006-03-29 2012-07-11 International Institute of Cancer Immunology, Inc. Für die isoform wt1 17aa(-) spezifische sirna und verwendung davon
WO2007120673A2 (en) * 2006-04-10 2007-10-25 Sloan Kettering Institute For Cancer Research Immunogenic wt-1 peptides and methods of use thereof
EP2341142B8 (de) 2006-12-28 2015-01-14 International Institute of Cancer Immunology, Inc. HLA-A*1101-beschränktes WT1-Peptid und pharmazeutische Zusammensetzung damit
AU2012227350C1 (en) * 2006-12-28 2015-11-12 International Institute Of Cancer Immunology, Inc. HLA-A*1101-Restricted WT1 peptide and pharmaceutical composition comprising the same
KR101773690B1 (ko) 2007-03-05 2017-08-31 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 암 항원 특이적 ｔ 세포의 수용체 유전자 및 그것에 따라 코드되는 펩티드 및 이들의 사용
ITTO20070401A1 (it) * 2007-06-07 2008-12-08 Univ Degli Studi Torino Vaccino anti-tumorale
AR076349A1 (es) * 2009-04-23 2011-06-01 Int Inst Cancer Immunology Inc Peptido auxiliar del antigeno del cancer
WO2011059835A2 (en) * 2009-11-11 2011-05-19 Quest Diagnostics Investments Incorporated Wt1 mutations for prognosis of myeloproliferative disorders
CA2839663A1 (en) 2011-06-28 2013-01-03 International Institute Of Cancer Immunology, Inc. Receptor gene for peptide cancer antigen-specific t cell
EP2738253A4 (de) 2011-07-29 2015-04-22 Riken Zelle zur verwendung in der immuntherapie mit für wilms-tumorgenprodukt oder fragment davon codierendem modifiziertem nukleinsäurekonstrukt, verfahren zur herstellung dieser zelle und besagtes nukleinsäurekonstrukt
US10316332B2 (en) 2011-07-29 2019-06-11 Riken Cell for immunotherapy, including modified nucleic acid construct encoding Wilms tumor gene product
RU2633068C2 (ru) * 2011-09-14 2017-10-11 Интернешнл Инститьют Оф Кэнсер Иммунолоджи, Инк. Способ измерения антитела против wt1
JP6117515B2 (ja) * 2011-11-01 2017-04-19 国立大学法人名古屋大学 髄膜腫治療用医薬組成物
AU2013207669C1 (en) 2012-01-13 2018-05-31 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
RS61173B1 (sr) 2013-01-15 2021-01-29 Memorial Sloan Kettering Cancer Center Imunogeni wt-1 peptidi i postupci za njihovu upotrebu
US10815273B2 (en) 2013-01-15 2020-10-27 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
JP6250288B2 (ja) * 2013-01-30 2017-12-20 株式会社医学生物学研究所 Ｔ細胞レセプターおよびその利用
US10695385B2 (en) * 2015-06-25 2020-06-30 National University Corporation Kobe University Oral cancer vaccine
CN109890408A (zh) * 2016-05-27 2019-06-14 埃特彼塞斯公司 新表位疫苗组合物及其使用方法
US12383608B2 (en) 2016-11-30 2025-08-12 Sumitomo Pharma Co., Ltd. WT1 helper peptides and combinations of WT1 helper peptide and conjugate of cancer antigen peptides
JPWO2018181648A1 (ja) 2017-03-30 2020-02-13 大日本住友製薬株式会社 Ｗｔ１癌抗原ペプチドおよびこれを含むペプチドコンジュゲート体
EP3634449A4 (de) 2017-05-08 2021-03-17 Gritstone Oncology, Inc. Alphavirus-neoantigen-vektoren
MX2020007077A (es) 2018-01-04 2020-10-28 Iconic Therapeutics Inc Anticuerpos anti-factor tisular, conjugados anticuerpo-farmaco y metodos relacionados.
JP2021533759A (ja) * 2018-08-10 2021-12-09 ユーティレックス カンパニー リミテッド 癌抗原特異的ｃｄ８＋ｔ細胞を調製および凍結保存するための方法
JP7162675B2 (ja) 2018-09-28 2022-10-28 住友ファーマ株式会社 注射用組成物
MX2021014525A (es) 2019-05-30 2022-03-17 Gritstone Bio Inc Adenovirus modificados.
JP7153287B2 (ja) 2020-05-12 2022-10-14 住友ファーマ株式会社 癌を処置するための医薬組成物
CN116438308A (zh) 2020-08-06 2023-07-14 磨石生物公司 多表位疫苗盒
MX2024001843A (es) 2021-08-12 2024-05-16 Int Inst Cancer Immunology Inc Composición farmacéutica y método para tratar o prevenir cáncer.
CN115998851A (zh) * 2022-12-28 2023-04-25 四川康德赛医疗科技有限公司 一种个体化mRNA组合物、载体、mRNA疫苗及其应用
CN117552115B (zh) * 2024-01-12 2024-03-26 天津鲸鹏生物科技有限责任公司 用于诱导肿瘤特异性免疫响应的通用型抗原肽库及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3393867B2 (ja) * 1989-11-13 2003-04-07 マサチユーセツツ・インステイテユート・オブ・テクノロジー ウィルムス腫瘍遺伝子の位置決定と特徴付け
JP3435163B2 (ja) * 1993-07-20 2003-08-11 ロシュ ダイアグノスティクス ゲゼルシャフト ミット ベシュレンクテル ハフツング 黒色腫阻害蛋白質
AR021849A1 (es) * 1998-09-30 2002-08-07 Corixa Corp Composiciones y metodos para la inmunoterapia especifica de wt1
CA2401070A1 (en) * 2000-02-22 2001-08-30 Corixa Corporation Compositions and methods for diagnosis and therapy of malignant mesothelioma

Also Published As

Publication number Publication date
WO2002028414B1 (en) 2002-07-18
JP2008154588A (ja) 2008-07-10
WO2002028414A1 (en) 2002-04-11
DE60135005D1 (de) 2008-09-04
EP1328287B1 (de) 2008-07-23
MXPA03002983A (es) 2004-12-06
US20030072767A1 (en) 2003-04-17
CN1505526A (zh) 2004-06-16
JP2004510425A (ja) 2004-04-08
AU2001296608B2 (en) 2007-05-24
CA2425072A1 (en) 2002-04-11
ES2311027T3 (es) 2009-02-01
CA2425072C (en) 2013-11-26
EP1328287A1 (de) 2003-07-23
JP4130359B2 (ja) 2008-08-06
KR20030081314A (ko) 2003-10-17
NZ540397A (en) 2008-05-30
KR100858231B1 (ko) 2008-09-12
AU9660801A (en) 2002-04-15
EP1328287A4 (de) 2005-09-07
CN100545174C (zh) 2009-09-30

Similar Documents

Publication Publication Date Title
ATE402189T1 (de) Verbindungen und methoden zur wt1-spezifischen immuntherapie
ATE429442T1 (de) Zusammensetzungen und verfahren zur wt1- spezifischen immuntherapie
TW200509967A (en) Compositions and methods for WT1 specific immunotherapy
TW200606176A (en) Compositions and methods for wt1 specific immunotherapy
WO2001025273A3 (en) Compositions and methods for wt1 specific immunotherapy
MY136095A (en) Use of human anti-ctla-4 antibodies for treatment of cancer
HUP0302532A2 (hu) Petefészekrák terápiájában és diagnosztizálásában alkalmazható készítmények és eljárások
CY1107862T1 (el) Φαρμακευτικες συνθεσεις που περιλαμβανουν παραγωγα οιστερολης για χρηση στη θεραπεια του καρκινου
WO2004058171A3 (en) Antibodies against gpr64 and uses thereof
DK1187632T3 (da) Behandling med anti-ErbB2-antistoffer
ATE294591T1 (de) Verwendung von trifunktionellen bispezifischen und trispezifischen antikörpern zur behandlung von malignem aszites
EA202191257A1 (ru) Противораковая терапия на основе иммуноцитов, связывающих liv1
HUP0300590A2 (hu) Peptidázzal hasítható, célzott antineoplasztikus szerek és terápiás alkalmazásuk
DE602004015811D1 (de) Verfahren zur inhibierung der proliferation von tumorzellen, bei dem platinkomplexe eingesetzt werden
DE60021381D1 (de) Chinonverbindungen zur behandlung von krankheiten
TR199700999T1 (xx) Askomisinler.
WO2002047613A3 (en) Immunogenic cancer peptides and uses thereof
NO20030420L (no) Medikament for immunoterapi av maligne tumorer
ATE475710T1 (de) Zusammensetzungen und verfahren für die therapie und diagnose von ovariumkrebs
MXPA05009428A (es) Composiciones y metodos para prevenir y tratar enfermedades relacionadas con endotoxinas.
WO2003024304A3 (en) Detection and treatment of cancers of the liver
ZA202407599B (en) Antibodies that specifically bind to api5 protein
NO20062358L (no) Jombinasjoner for behandling av proliferative sykdommer

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties